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Lipopeptidomimetics Derived from Teixobactin have Potent 
Antibacterial Activity against Staphylococcus aureus 
Georgina. C. Girt,a Amit Mahindra,c Zaaima. J. H. Al Jabri,b Megan De Ste Croix,b Marco. R. Oggionib 
and Andrew. G. Jamieson*c 
A series of lipopeptidomimetics derived from Teixobactin have 
been prepared that probe the role of residues (1 – 6) as a 
membrane anchor and the function of enduracididine. The most 
active compounds, with a farnesyl tail and End10 to Lys10 or 
Orn10 substitution have potent activity (MIC 8 g/mL) against S. 
aureus. These results pave the way for the synthesis of simple, 
cost-effective yet potent lipopeptidomimetic antimicrobials. 
The emergence of antimicrobial resistance is becoming a 
global crisis, with even last-resort antibiotics giving rise to 
resistant strains.1 Teixobactin, discovered from previously 
uncultivable bacteria, gave way to a new class of antibiotics.2,3 
Teixobactin appears to have multiple modes of action, 
preventing the rapid onset of resistance.4,5 For example 
inhibition of both peptidoglycan and teichoic acid synthesis is 
achieved through binding multiple bactoprenol-coupled cell 
wall precursors including lipid II.4 This key building block is 
involved in the rate-limiting step of peptidoglycan biosynthesis 
and so is essential for the production of the bacterial cell wall.5  
Teixobactin is an undecapeptide antibiotic comprised of a 
depsipeptide macrocycle, linked to a largely hydrophobic 
linear peptide tail. The native compound contains four D-
amino acids, and the nonproteinogenic residue L-allo-
enduracididine (L-allo-End).2 The cyclic depsipeptide 
component of Teixobactin has recently been shown to form 
hydrogen-bonding interactions with chloride anions and has 
been proposed as a pyrophosphate recognition motif.6 
Lantibiotics such as nisin have also been found to form such a 
pyrophosphate cage;7 thus increasing membrane permeation 
through pore formation.8  
Since the original report describing the isolation and bio-
activity of teixobactin, total syntheses have been reported by 
the Li and Payne groups.9,10 A solution phase synthesis of the 
cyclic depsipeptide ring has also been reported.11 However, 
the synthesis of Teixobactin is both laborious due to the seven 
step synthesis of L-allo-End and relatively expensive because 
four D-amino acids are required. Development of simpler, 
more cost-effective peptidomimetics is therefore an attractive 
alternative. Recently, a number of Teixobactin analogues that 
are simpler to produce have been described. Several groups 
have reported the synthesis and antimicrobial activity of 
analogues in which the non-proteinogenic L-allo-
enduracididine residue is substituted with isosteric amino 
acids.12-15 A Fmoc-solid phase peptide synthesis (SPPS) strategy 
was employed, with orthogonal protection to give the 
branched side chain, before cyclisation to form the 13-
membered depsipeptide ring in solution. The Teixobactin 
analogue with single End10 to Arg amino acid substitution was 
found to have substantial antimicrobial activity, with a 
minimum inhibitory concentration (MIC) value of 2 g/mL, yet 
still 8 times weaker than Teixobactin.  
The Singh group investigated the role of amino acid 
stereochemistry through production of Arg10 analogues of 
Teixobactin incorporating L-amino acids and acetylated at the 
N-terminus, all of which gave a reduction in antibiotic activity 
against Gram-positive bacteria.13,14 The role of each 
independent mutation was then clarified by the Albericio and 
co-workers, who found that mutation to all L-amino acids with 
retention of the native N-terminus eradicated all antibiotic 
activity., Acetylation of the N-terminus as the sole alteration 
resulted in negligible activity with an MIC of 256 g/mL for B. 
subtilis.16       
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  Subsequently, Nowick and co-workers reported the synthesis 
and antimicrobial activity of several new Teixobactin 
analogues, mutating the enduracididine residue, the 
stereochemistry of various residues, cleaving the depsipeptide 
bond of the macrocyclic ring, and replacing part of the linear 
peptide tail of the Arg10 analogue with a dodecanoyl group.17 
Interestingly, these results showed that mutating 
enduracididine to a lysine residue rather than arginine resulted 
in better antimicrobial activity (MIC of 0.25 g/mL compared 
to 1 g/mL against S. epidermis). In addition¸ replacement of 
residues 1 – 5 with a hydrocarbon chain gave an effective 
antibiotic with an MIC of 4 µg/mL.  
Structure-activity-relationship studies have also revealed the 
importance of polar residues using a selective lysine scan.18,19 
The hydroxyl group of the Ser7 residue was also identified as 
significant through substitution to Ala and the alkylation state 
of the N-terminal Phe1 residue is important to the 
antibacterial activities of these analogues.  
However, the functional role of the peptide tail (residues 1-6) 
has not been extensively studied and no lipidated 
peptidomimetic has been created that retains comparable 
activity of native Teixobactin. The aim of this work was to 
investigate the role of residues 1 - 7 as a potential membrane 
anchor by developing lipopeptidomimetics with lipids of 
different lengths and evaluate the effect of substitution of 
End10 to amino acids with different side-chain functionality.  
Isoprenoid chains are known to be effective cellular membrane 
anchors,20 and prenylation of cysteine residues is a commonly 
occurring post-translational modification (PTM) in eukaryotic 
proteins. The dependence on isoprenoid length for cell 
penetration has previously been explored.21 Prenylated 
peptidomimetics have the potential to serve as more cost-
effective alternatives to teixobactin as antibiotic drugs.  
Teixobactin contains a Ser at the 7-position, it was therefore 
rationalised that substitution to an cysteine residue would 
facilitate prenylation without significant adverse effect on 
activity. Our rational was that replacing the peptide tail (1 – 6), 
including three D-amino acids, with a farnesyl lipid chain would 
provide a lipopeptidomimetic analogue requiring fewer 
synthetic steps and only commercially available L-amino acids. 
The basic guanidinium functionality of allo-enduracididine 
within Teixobactin is important for biological activity. We 
therefore investigated a number of different bioisostere amino 
acid residues including arginine and lysine. As controls, neutral 
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(Ala10) and acidic (Glu10) macrocyclic analogues were also 
prepared (See SI).  
The synthesis of Arg10-farnesylbactin 1 and related analogues 
2 - 7 was carried out via Fmoc-SPPS followed by solution-phase 
macrocyclisation (Scheme 1). Initially, Fmoc-Ala-OH was 
coupled to 2-chlorotrityl resin with DIEA in DCM, before 
threonine and cysteine were coupled, and the N-terminal 
acetylated using acetic anhydride. No capping of the hydroxyl 
threonine side chain was observed by LCMS on a small sample 
cleaved from the solid support. The depsipeptide ester linkage 
was then formed using Fmoc-Ile-OH, DIC and catalytic DMAP.  
The isoleucine Fmoc protecting group was removed and 
arginine (or appropriate amino acid) coupled under standard 
conditions, with no diketopiperizine formation detected. 
Following deprotection the peptide was cleaved from the solid 
support under mildly acidic conditions (1% TFA/DCM).  
Macrocyclisation of the Ala9 C-terminal to Arg10 N-terminus 
was easily achieved through amide coupling using HATU and 
DIEA. This reaction was found to proceed extremely efficiently 
with >99% conversion from linear to cyclic forms, as 
determined by RP-HPLC. Finally, the trityl protecting group was 
removed from the cysteine side chain to yield a free thiol and 
the farnesyl chain was attached using catalytic Zn(OAc)2.2H2O 
and TFA. The final product was purified by RP-HPLC and 
characterised by HRMS, 1H NMR and TOCSY NMR. 
Lipopeptidomimetic Arg10-farnesylbactin 1 was then evaluated 
against the Gram-positive bacterial strain Staphylococcus 
aureus ATCC 25923 and the Gram-negative bacterial strain 
Escherichia coli ATCC 25922 (table 1). We were encouraged to 
observe that this compound was active (8 g/mL) in the 
minimum inhibitory concentration assays against Gram-
positive but not Gram-negative bacteria and thus showed a 
similar trend of activity as teixobactin. In order to further 
investigate the effect of substituting the allo-enduracididine 
residue we produced a series of analogues with varying 
functionality at position 10 (Table 1). Lys10-farnesylbactin 2 
was designed as a result of a previous report suggesting that 
lysine is a better mimic of the enduracididine residue than 
arginine.15 This proved to be the case and provided compound 
2 as a more potent analogue (8 g/mL). Surprisingly 
compound 2 was also active against the negative Escherichia 
coli bacterial strain. 
Orn10-farnesylbactin 3 provides an analogue with shorter 
amine side-chain. This analogue has comparable activity in 
both the S. aureus MIC (8 g/mL) and MBC (16 g/mL) assays 
relative to the corresponding Lysine analogue 2. 
To investigate the effect of the charge and potential for the 
side-chain of residue10 to form electrostatic interactions, Cit10-
farnesylbactin 4 was produced which is neutral in terms of 
charge, however can still H-bond; His10-farnesylbactin 5 with 
partial positive charge; Ala10-farnesylbactin 6 in which the side-
chain is removed altogether and Glu10-farnesylbactin 7 with 
negative charge were produced. Interestingly, all of these 
analogues showed a total lack of activity (Table 1).  
Next, we examined whether a shorter geranyl (C8) isoprenoid 
chain would also provide active lipopeptidomimetic analogues. 
A further set of compounds without hydrocarbon tails were 
synthesised as controls; comprising of a cyclic 
tetradepsipeptide with an N-terminal acetyl cap (see Figure 
S1). 
None of these compounds (Table 1, compounds 8 - 14), had 
antibiotic activity against Gram-positive bacteria S. aureus. 
Interestingly, the arginine, lysine and ornithine equivalents (8, 
9 and 10) did not show any activity, unlike their farnesylated 
	
Compound	
S.	aureus	ATCC	25923	 E.	coli	ATCC	25922	
MIC	 MBC	 MIC	
Arg10-farnesylbactin	(1)	 16	 >32	 >32	
Lys10-farnesylbactin	(2)	 8	 16	 16	
Orn10-farnesylbactin	(3)	 8	 16	 32	
Cit10-farnesylbactin	(4)	 >32	 >32	 >32	
His10-farnesylbactin	(5)	 >32	 >32	 >32	
Ala10-farnesylbactin	(6)	 >32	 >32	 >32	
Glu10-farnesylbactin	(7)	 >32	 >32	 >32	
Arg10-geranylbactin	(8)	 >32	 >32	 >32	
Lys10-geranylbactin	(9)	 >32	 >32	 >32	
Orn10-geranylbactin	(10)	 >32	 >32	 >32	
Cit10-geranylbactin	(11)	 >32	 >32	 >32	
His10-geranylbactin	(12)	 >32	 >32	 >32	
Ala10-geranylbactin	(13)	 >32	 >32	 >32	
Glu10-geranybactin	(14)	 >32	 >32	 >32	
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counterparts suggesting that slight changes in structure can 
result in diminished biological activity. 
Of the lipopeptidomimetics investigated, only basic residues 
were found to have any antibiotic activity, suggesting that the 
positive charge and thus potentially an electrostatic 
interaction with the binding partner(s) is crucial for function. 
These results are also consistent with previous research that 
suggests that the mutation of L-allo-enduracididine to lysine, 
rather than the more structurally similar arginine, is in fact 
advantageous for antibiotic activity.17 The importance of the 
hydrophobic tail is also apparent, as the control cyclic 
tetradepsipeptides 15 - 17 were not active against either strain 
of bacteria (See SI).  
In conclusion, the rational design of Teixobactin 
lipopeptidomimetics has been achieved. Replacing the 
hydrophobic linear peptide tail (1 – 7) with isoprenoid 
surrogates of differing length provided biologically active 
analogues. A structure-activity-relationship study to 
investigate the function of enduracididine on antibacterial 
activity revealed the importance of a positively charged side-
chain at residue 10. Finally, lipopeptidomimetics 1, 2 and 3 are 
the first examples of farnesyl lipidated teixobactin analogues 
with antibacterial activity, representing promising lead 
compounds for drug discovery. 
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